Summary
Steve Ruben is a biotech founder and proteomics leader with 13+ years steering discovery programs from mass spectrometry–driven biomarker identification to IND-enabling target validation. As Founder and President of SMR Bio Consulting and former VP of Proteomics at Celera, he has built and overseen high-throughput MS discovery, cell biology, and functional validation labs focused on oncology indications including lung, colon and pancreatic cancer. He combines deep hands-on expertise in assay development, immunohistochemistry, RNAi functional studies and bioinformatics to translate proteomic hits into diagnostic panels and therapeutic antibody/small-molecule opportunities. He has a proven track record of coordinating discovery with preclinical, clinical and regulatory teams and establishing academic and commercial partnerships for validation and commercialization. Notably, he applies complex comparative proteomic strategies to derive pharmacoproteomic predictive markers rather than relying on single-analyte findings. Trained with a PhD in Molecular/Cell Biology, he brings both technical depth and entrepreneurial judgment to early-stage translational programs.
13 years of coding experience
Ph.D. M.S., Molecular/Cell Biology, Ph.D. M.S., Molecular/Cell Biology at University of Cincinnati
Bachelor of Science (B.S.), Biochemistry, Bachelor of Science (B.S.), Biochemistry at The Ohio State University